Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | — | — | — | — | — | -$3.50M | -$2.63M | -$1.40M | -$880K | -$616K |
| Net income | -$1.27M | -$45.4K | -$1.21M | -$798K | -$1.06M | -$3.68M | -$2.38M | -$1.01M | -$922K | -$688K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.55 | -$0.33 | -$0.14 | -$0.13 | -$0.10 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.58M | -$1.31M | -$880K | -$761K | -$987K | -$679K | -$690K | -$497K | -$241K | -$111K |
| Capital expenditures | $0.00 | $2.70K | $1.47K | $0.00 | — | — | — | — | — | — |
| Free cash flow | -$1.58M | -$1.31M | -$882K | -$761K | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.16M | $980K | $2.30M | $787K | $353K | $226K | $221K | $156K | $115K | $3.62K |
| Total assets | $3.82M | $3.76M | $2.58M | $1.92M | $458K | $269K | $261K | $180K | $142K | $19.9K |
| Total liabilities | $73.5K | $56.6K | $84.8K | $228K | $880K | $3.07M | $5.15M | $6.05M | $6.93M | $7.50M |
| Shareholders' equity | $3.75M | $3.70M | $2.50M | $1.70M | -$423K | -$2.80M | -$4.88M | -$5.87M | -$6.79M | -$7.48M |
| Retained earnings | -$59.1M | -$59.1M | -$60.3M | -$61.1M | -$843K | -$4.53M | -$6.91M | -$7.92M | -$8.84M | -$9.53M |
| Shares (wtd avg diluted) | 399M | 399M | 399M | 399M | 399M | 6.71M | 7.24M | 7.24M | 7.24M | 7.24M |
Every figure is extracted from Mosaic ImmunoEngineering Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.